Xponance Inc. Purchases 525 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Xponance Inc. raised its position in Blueprint Medicines Co. (NASDAQ:BPMC) by 12.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,781 shares of the biotechnology company’s stock after purchasing an additional 525 shares during the period. Xponance Inc.’s holdings in Blueprint Medicines were worth $417,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of BPMC. Quarry LP acquired a new position in shares of Blueprint Medicines in the 3rd quarter valued at $32,000. R Squared Ltd acquired a new position in Blueprint Medicines in the fourth quarter valued at about $51,000. Asset Management One Co. Ltd. bought a new stake in shares of Blueprint Medicines in the fourth quarter worth about $88,000. Van ECK Associates Corp raised its position in shares of Blueprint Medicines by 48.2% during the fourth quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 363 shares during the period. Finally, Quantbot Technologies LP bought a new position in shares of Blueprint Medicines during the 3rd quarter valued at about $108,000.

Blueprint Medicines Stock Performance

Shares of BPMC opened at $90.72 on Thursday. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The firm has a 50-day moving average of $98.84 and a 200-day moving average of $93.95. The company has a market cap of $5.80 billion, a PE ratio of -84.00 and a beta of 0.58. Blueprint Medicines Co. has a one year low of $80.68 and a one year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, equities analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Wolfe Research initiated coverage on Blueprint Medicines in a research note on Tuesday, March 18th. They set an “outperform” rating for the company. Jefferies Financial Group initiated coverage on shares of Blueprint Medicines in a report on Monday, March 17th. They set a “buy” rating and a $135.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on shares of Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Needham & Company LLC reissued a “buy” rating and issued a $133.00 price target on shares of Blueprint Medicines in a research note on Thursday, February 13th. Finally, Stephens restated an “overweight” rating and issued a $140.00 price target on shares of Blueprint Medicines in a report on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $124.95.

Insiders Place Their Bets

In related news, insider Ariel Hurley sold 2,250 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $100.00, for a total value of $225,000.00. Following the transaction, the insider now owns 14,967 shares in the company, valued at approximately $1,496,700. This represents a 13.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kate Haviland sold 1,446 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the sale, the chief executive officer now owns 149,378 shares of the company’s stock, valued at $16,467,430.72. This trade represents a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 31,608 shares of company stock valued at $3,319,587 over the last ninety days. 4.21% of the stock is currently owned by company insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.